Pharmacogenetics implementation in the clinics : information and guidelines for germline variants
© The Author(s) 2019..
The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group). A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Cancer drug resistance (Alhambra, Calif.) - 2(2019), 1 vom: 21., Seite 53-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olivera, Gladys [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical implementation |
|---|
| Anmerkungen: |
Date Revised 19.05.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.20517/cdr.2018.25 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34104931X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34104931X | ||
| 003 | DE-627 | ||
| 005 | 20231226010857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20517/cdr.2018.25 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM34104931X | ||
| 035 | |a (NLM)35582138 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olivera, Gladys |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics implementation in the clinics |b information and guidelines for germline variants |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.05.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2019. | ||
| 520 | |a The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group). A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PharmGKB | |
| 650 | 4 | |a Pharmacogenetic | |
| 650 | 4 | |a Polymorphisms | |
| 650 | 4 | |a clinical implementation | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a oncology | |
| 700 | 1 | |a Sendra, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Herrero, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Berlanga, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Gargallo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Yáñez, Yania |e verfasserin |4 aut | |
| 700 | 1 | |a Urtasun, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a de Mora, Jaime Font |e verfasserin |4 aut | |
| 700 | 1 | |a Castel, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Cañete, Adela |e verfasserin |4 aut | |
| 700 | 1 | |a Aliño, Salvador F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer drug resistance (Alhambra, Calif.) |d 2018 |g 2(2019), 1 vom: 21., Seite 53-68 |w (DE-627)NLM292424043 |x 2578-532X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2019 |g number:1 |g day:21 |g pages:53-68 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20517/cdr.2018.25 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2019 |e 1 |b 21 |h 53-68 | ||